ClinicalTrials.gg
CompletedNCT01217606Updated Dec 20, 2016Results posted

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) and Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-20.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.

Enrollment
14th of 29
185 · median 169
Started
2011
with 5 others
Phase 3
9 of 29
1 open now
Registered
4th of 29
by date
Lead sponsor
17 of 29
Allergan

Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 14th largest by enrollment, is one of 6 that started in 2011, is one of 9 in phase 3, and was the 4th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimatoprost

Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing bimatoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ocular hypertension or primary open-angle glaucoma in each eye
  • Requires treatment with IOP-lowering medication in both eyes

Exclusion criteria

Exclusion Criteria:

  • Required chronic use of ocular medications during the study other than study medication
  • Use of any within 30 days
  • History of any traumatic eye surgeries
  • Cataract surgery in the past 6 months
  • Anticipated wearing of contact lenses during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    Triple Combination Therapy

    Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.

    Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

  • Active comparator
    Combigan®

    Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.

    Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

Interventions

  • Drugbimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

    Drug pages: Bimatoprost · Brimonidine · Timolol

    One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.

  • DrugFixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

    One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.

    Also known as: COMBIGAN®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test

    Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed using a two-sample t-test.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure

    Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed by a mixed-effect model for repeated measure.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Month 6, Month 9, Month 12

  2. Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)

    Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed by ANCOVA.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Month 6, Month 9, Month 12

07

Results

Posted Nov 9, 2015

Participant flow

Initial Treatment Phase
Participant flow — Initial Treatment Phase
MilestoneTriple Combination TherapyCombigan®
Started9095
Completed7683
Not completed1412
Withdrew: Other reasons02
Withdrew: Protocol violation32
Withdrew: Personal reasons02
Withdrew: Lack of efficacy10
Withdrew: Adverse event106
9-Month Masked Extension
Participant flow — 9-Month Masked Extension
MilestoneTriple Combination TherapyCombigan®
Started6773
Not enrolled in masked extension910
Completed5462
Not completed1311
Withdrew: Adverse event36
Withdrew: Other reasons44
Withdrew: Personal reasons21
Withdrew: Lost to follow-up10
Withdrew: Pregnancy10
Withdrew: Lack of efficacy20

Outcome measures

PrimaryChange From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test

Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed using a two-sample t-test.

Time frame:
Baseline, Week 12
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test
Millimeters of Mercury (mmHg)Triple Combination TherapyCombigan®
Baseline25.42 ± 2.90224.43 ± 2.592
Change from Baseline at Week 12 (N=85, 93)-10.45 ± 3.175-8.28 ± 3.256
SecondaryChange From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure

Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed by a mixed-effect model for repeated measure.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Month 6, Month 9, Month 12
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure
Millimeters of Mercury (mmHg)Triple Combination TherapyCombigan®
Baseline25.42 ± 2.90224.43 ± 2.592
Change from Baseline at Week 1 (N=82, 91)-11.63 ± 3.060-8.13 ± 2.969
Change from Baseline at Week 2 (N=82, 87)-11.24 ± 3.283-8.12 ± 2.942
Change from Baseline at Week 4 (N=82, 88)-10.88 ± 3.193-8.35 ± 3.100
Change from Baseline at Week 8 (N=75, 87)-10.53 ± 3.165-7.94 ± 3.453
Change from Baseline at Week 12 (N=76, 83)-10.56 ± 3.224-8.16 ± 3.161
Change from Baseline at Month 6 (N=64, 69)-10.41 ± 2.976-8.29 ± 3.221
Change from Baseline at Month 9 (N=58, 67)-10.29 ± 3.275-8.14 ± 2.937
Change from Baseline at Month 12 (N=55, 63)-9.38 ± 3.398-7.58 ± 3.486
SecondaryChange From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)

Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed by ANCOVA.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Month 6, Month 9, Month 12
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)
Millimeters of Mercury (mmHg)Triple Combination TherapyCombigan®
Baseline25.42 ± 2.90224.43 ± 2.592
Change from Baseline at Week 1 (N=82, 91)-11.63 ± 3.060-8.13 ± 2.969
Change from Baseline at Week 2 (N=84, 92)-11.20 ± 3.290-8.28 ± 3.076
Change from Baseline at Week 4 (N=85, 93)-10.85 ± 3.180-8.53 ± 3.228
Change from Baseline at Week 8 (N=85, 93)-10.44 ± 3.105-8.07 ± 3.521
Change from Baseline at Week 12 (N=85, 93)-10.45 ± 3.175-8.28 ± 3.256
Change from Baseline at Month 6 (N=67, 73)-10.32 ± 2.965-8.42 ± 3.252
Change from Baseline at Month 9 (N=67, 73)-10.09 ± 3.349-8.17 ± 3.031
Change from Baseline at Month 12 (N=67, 73)-9.36 ± 3.368-7.77 ± 3.489

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triple Combination Therapy—1/90 (1.1%)84/90 (93.3%)
Combigan®—1/95 (1.1%)77/95 (81.1%)
Most frequent serious events
Most frequent serious events
EventTriple Combination TherapyCombigan®
Rotator Cuff SyndromeMusculoskeletal and connective tissue disorders1/900/95
Tendon ruptureInjury, poisoning and procedural complications0/901/95
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTriple Combination TherapyCombigan®
Conjunctival hyperaemiaEye disorders54/9028/95
Punctate keratitisEye disorders25/9019/95
BlepharitisEye disorders15/9012/95
Conjunctival folliclesEye disorders7/9015/95
Eye pruritusEye disorders12/907/95
Eye irritationEye disorders11/903/95
MeibomianitisEye disorders10/908/95
Erythema of eyelidEye disorders9/907/95
CataractEye disorders8/903/95
Visual Field DefectNervous system disorders7/907/95

Baseline characteristics

Age, Customized
Age, Customized(Participants)Triple Combination TherapyCombigan®Total
≤65 years6862130
>65 years223355
Gender
Gender(Participants)Triple Combination TherapyCombigan®Total
Female5363116
Male373269
08

Study locations

1 site
  • São Paulo, Brazil
09

References and documents

Publications

  • Belfort R Jr, Paula JS, Lopes Silva MJ, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil☆. Clin Ther. 2020 Feb;42(2):263-275. doi: 10.1016/j.clinthera.2019.12.008. Epub 2020 Feb 20. PubMed 32089329 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Sep 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2010
First posted
Oct 8, 2010
Start
Jan 2011
Primary completionActual
Sep 2014
CompletionActual
Jun 2015
Results first posted
Nov 9, 2015
Last update
Dec 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01217606
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 8, 2010
Start date
Jan 2011
Primary completion
Sep 2014
Completion
Jun 2015
Results posted
Nov 9, 2015
Last update
Dec 20, 2016

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimatoprost · Brimonidine · Timolol

Start the discussion